Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Average Price Target from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned an average rating of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $41.44.

Several equities analysts have commented on the stock. B. Riley reiterated a “buy” rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $13.82 on Thursday. The business’s 50-day moving average is $18.13 and its 200 day moving average is $19.61. Arrowhead Pharmaceuticals has a 12 month low of $13.66 and a 12 month high of $30.41. The company has a market capitalization of $1.90 billion, a P/E ratio of -2.67 and a beta of 0.92. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, equities research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, COO Patrick O’brien sold 29,184 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $578,426.88. Following the completion of the sale, the chief operating officer now owns 535,201 shares in the company, valued at approximately $10,607,683.82. The trade was a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the transaction, the chief executive officer now owns 3,764,252 shares in the company, valued at $71,709,000.60. The trade was a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 286,317 shares of company stock valued at $5,049,735 in the last quarter. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 11.5% in the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company’s stock worth $2,401,000 after acquiring an additional 12,706 shares during the period. Intech Investment Management LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $659,000. Erste Asset Management GmbH purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $924,000. Geode Capital Management LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after purchasing an additional 26,171 shares in the last quarter. Finally, State Street Corp increased its holdings in Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock valued at $123,083,000 after buying an additional 516,569 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.